SBC101
Idiopathic Pulmonary Fibrosis (IPF)
Pre-IND / Preparing for Phase 1Active
Key Facts
Indication
Idiopathic Pulmonary Fibrosis (IPF)
Phase
Pre-IND / Preparing for Phase 1
Status
Active
Company
About SapiensBio
SapiensBio is a preclinical-stage biotech utilizing its AI platform, Sapientia, for novel drug discovery, with a focus on idiopathic pulmonary fibrosis. Its lead candidate, SBC101, has received positive FDA Pre-IND feedback and is preparing for Phase 1 trials. The company is actively pursuing licensing deals and investment, positioning itself at a key inflection point as it transitions into clinical development.
View full company profileTherapeutic Areas
Other Idiopathic Pulmonary Fibrosis (IPF) Drugs
| Drug | Company | Phase |
|---|---|---|
| OATD-01 | Molecure | Phase II |
| FP-020 (BMS-986235) | Foresee Pharmaceuticals | Phase 2 |
| Buloxibutid (C21) | Vicore Pharma | Phase 2b |
| AP02 | Avalyn Pharmaceuticals | Phase 2 |
| Gento-Fibrose Pulmonaire Program | Genoscience Pharma | Preclinical |
| SM001 (alidornase/Tigerase) | SarcoMed USA | Research |
| NLM-001 | Nelum Pharma | Phase 1 |
| GNS-3545 (ROCK2 Inhibitor) | Genosco | Phase 1 |
| TG2 Inhibitor Program | Isterian Biotech | Preclinical |
| Taladegib (ENV-101) | Endeavor BioMedicines | Phase 2b |
| CAL101 | Calluna Pharma | Phase 2 |
| NVP-13 | Velvio | Pre-clinical |